Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Shareholder Meeting (June 2022)
20 slides from Regeneron Pharmaceuticals's shareholder meeting presentation, Jun 10, 2022
Slide 1: 2022 Annual Shareholder Meeting Presentation
J u n e 1 0 , 2 0 2 2 2 0 2 2 A N N U A L S H A R E H O L DE R M E E T I N G P R E S E N TATI O N
Slide 2: Note regarding forward-looking statements & non-GAAP financial measures
Note regarding forward-looking statements & non-GAAP financial measures This presentation includes forw ard-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Phar maceuticals, Inc. (w here applicable, together w ith its subsidia
Slide 3: Executing on Core Competencies, Investing in Regeneron, Looking Ahead
Executing on Our Investing in Looking Ahead Core Competencies Regeneron to the Future Expect to ~35 therapeutic candidates #1 prescribed FDA invest ~$3.4 in various stages of clinical approved anti-VEGF billion1 into development treatment for retinal disease Advancing a Research and best-in-class, D
Slide 4: Delivered Strong Results in 2021 Across the Organization
Delivered Strong Results in 2021 Across the Organization 2021 R&D Pipeline Advancements AFLIBERCEPT Positive Ph2 results for Aflibercept 8mg in wAMD 8MG Positive Ph3 results in four potential new indications (EoE, pediatric AD 6mo-5yr, CSU, PN) Received approval in asthma for 2021 +89% YoY children
Slide 5: Continued to Drive Strong Results in 1Q22
Continued to Drive Strong Results in 1Q22 1H’2022 R&D Pipeline Advancements AFLIBERCEPT Encouraging Ph2 results for Aflibercept 8mg in wAMD 8MG EC approval for pediatric asthma (6yr- 11yr) FDA approvals for EoE & pediatric AD (6mo-5yr) 1Q 2022 Positive results for second Ph3 in PN, +25% YoY sBLA sub
Slide 6: EYLEA: 10+ Years of Patient Impact
EYLEA®: 10+ Years of Patient Impact Extending leadership position based on efficacy and safety that has transformed millions of lives; 50+ million doses administered worldwide since launch Developed using our proprietary Trap technology, development of aflibercept began in 2004 and became Regeneron’
Slide 7: Dupixent: Strong Performance Across All Approved Indications
Dupixent®: Strong Performance Across All Approved Indications With Significant Opportunity For Sustained Growth ~$6.2Bn FY2021 global net product sales Net Product Sales, $Million $426 $485 Atopic U.S. ROW $406 Dermatitis Asthma CRSwNP EoE $352 $1,348 $1,326 $1,257 $301 $1,147 $962 2.2M* 975k 90k 48
Slide 8: Dupixent: Near- and Long-Term Opportunities to Drive Growth
Dupixent®: Near- and Long-Term Opportunities to Drive Growth Estimated regulatory submission timeline for new indications Up to 4M+ 2022e 2023e 2024+e Eligible Patients Additional ~450k Addressable Population Additional ~375k Addressable Population Bullous Type 2 Prurigo Pemphigoid COPD Nodularis No
Slide 9: Proven Capability & Continued Commitment to Addressing COVID-19
Proven Capability & Continued Commitment to Addressing COVID-19 Rapid response technology, infectious disease expertise, large pool of antibody candidates NEXT GENERATION ANTIBODY candidates active 2021 against Omicron strains are currently being studied in Phase 1 Doses delivered* ~2.8M Regulatory
Slide 10: Regeneron to Purchase Global Rights to Libtayo
Regeneron to Purchase Global Rights to Libtayo Serve as • Positions Regeneron to become a global immuno-oncology leader Foundational • Enables flexibility to develop and commercialize Libtayo, expediting decision- Therapy making and development timelines • Maximizes upside of combination opportuniti
Slide 11: Unique Flexibility of Internally-Developed Pipeline Drives Novel Combinations
Unique Flexibility of Internally-Developed Pipeline Drives Potential for Novel and Differentiated Combinations CD3 Bispecifics: “Signal 1” Tumor-Targeted Biparatopics Odronextam ab BCMAxCD3 PSMAxCD3 MUC16xCD3 (CD20xCD3) (REGN5458) (REGN4336) (REGN4018) METxMET MET-altered R/R B-NHL, R/R Multiple Met
Slide 12: Synergistic Collaborations Supercharge Regeneron's Future
Synergistic Collaborations Supercharge Regeneron’s Future Turnkey Genetics Therapeutics Platforms Unlocking capabilities of mouse and Learnings from mouse genetics human genetics through Existing Turnkey Technologies Novel Turnkey Technologies Biologicals Gene Medicines siRNA Genome Gene TRAPs Antib
Slide 13: Regeneron Genetics Medicines
Regeneron is investing in and delivering REGENERON GENETICS technologies well beyond antibodies MEDICINES • 4 genetics medicines programs in the clinic Building the Pipeline for the Future • 3-5 additional potential targets to advance to IND-enabling studies in next 12 months Pre-IND Clinical Develo
Slide 14: Regeneron-Discovered, Approved and Investigational Medicines
Regeneron-Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases PHASE 1 PHASE 2 PHASE 3 APPROVED OR AUTHORIZED fianlimab (LAG-3) cemiplimab* (PD1) cemiplimab* (PD1) REGN5093 (METxMET) vidutolimod (TLR9) fianlimab (LAG-3) REGN5093-M114 (METxMET ADC) REGN4018 (MU
Slide 15: Multiple Potential FDA Submissions: 2022-2024+
Multiple Potential FDA Submissions: 2022-2024+ 2022 2023 2024+ EYLEA Itepekimab (IL-33)* Q16W in Non-Proliferative Diabetic Retinopathy (1H22) ✓ DUPIXENT* Bullous Pemphigoid Fianlimab (LAG3) + LIBTAYO Advanced Melanoma Chronic Obstructive Pulmonary Disease DUPIXENT* REGN4461 (LEPR) REGN1908-1909 (Fe
Slide 16: Key Upcoming Milestones (Next 12 Months)
Key Upcoming Milestones (Next 12 Months) Ophthalmology Solid Tumor Bispecifics • Ph3 data readout for Aflibercept 8mg formulation • Initial data for MUC16xCD3, PSMAxCD28 and METxMET Dupixent Odronextamab (CD20xCD3) • Report data for Ph 3 studies in EoE Pediatric (mid-2022), • Report potentially pivo
Slide 17: Regeneron's Disciplined Approach to Capital Allocation
Regeneron’s Disciplined Approach to Capital Allocation Internal Investment Anticipate spending ~$3.4 billion on R&D in 2022* in our world-class R&D capabilities and capital $1.8 billion investment in Tarrytown R&D facilities expenditures to support sustainable growth Continued investments in manufac
Slide 18: Advancing Responsible Business Practices & Shareholder Responsiveness
Advancing Responsible Business Practices & Shareholder Responsiveness Making significant progress towards our global 2025 Listening to our shareholders and remaining responsibility goals, spanning three strategic focus areas: committed to good corporate governance practices Improve the lives of peop
Slide 19: Reconciliation of GAAP Net Income to Non-GAAP Net Income
Reconciliation of GAAP Net Income to Non-GAAP Net Income 19 See slide 2 for additional important information regarding non-GAAP financial measures included in this presentation
Slide 20: Reconciliation of Total Revenue excluding REGEN-COV
Reconciliation of Total Revenue excluding REGEN-COV (casirivimab and imdevimab) 20 See slide 2 for additional important information regarding non-GAAP financial measures included in this presentation
Regeneron Pharmaceuticals — Shareholder Meeting (June 2022) on 6ix